1 While the in vitro
peroral absorption seemed to be less predictable, it ten
2 s at the 4N-position to optimize potency and
peroral absorption.
3 ty and overcome complications attendant with
peroral administration by developing a new nanovesicular
4 ic bioavailability of the gels compared with
peroral administration ranged from 54% to 69%.
5 have excellent pharmacokinetics in mice, and
peroral administration showed the compound to dose-depen
6 s of 13b-K after inhalative as well as after
peroral administration.
7 identity of the lung cell types targeted by
peroral arsenic and the associated immune mechanisms rem
8 Peroral arsenic has little effect on local airway immune
9 We aimed to determine the impact of
peroral arsenic on pulmonary antibacterial host defense.
10 nd higher polymers and is protective against
peroral challenges with T1L either when the MAb is passi
11 In recent years,
peroral cholangioscopy has evolved technologically and i
12 cuss the available data regarding the use of
peroral cholangioscopy in patients with PSC, with a focu
13 fficacy in the MDA-MB-231 xenograft model at
peroral doses ranging from 25 to 75 mg/kg.
14 cyclosporine A (CsA), a model peptide, upon
peroral dosing to rodents led to maximum plasma concentr
15 e proposed approach offers new prospects for
peroral drug delivery and beyond.
16 Gastric
peroral endoscopic myotomy (G-POEM) may be considered no
17 We included
peroral endoscopic myotomy (POEM) and gastric peroral en
18 Peroral endoscopic myotomy (POEM) and submucosal tunneli
19 Peroral endoscopic myotomy (POEM) for achalasia (sometim
20 e technique of submucosal space creation and
peroral endoscopic myotomy (POEM) has been used to treat
21 s of a large series of patients treated with
peroral endoscopic myotomy (POEM) in a single European c
22 Peroral endoscopic myotomy (POEM) is a less invasive the
23 Peroral endoscopic myotomy (POEM) is an increasingly uti
24 Pilot studies have indicated that
peroral endoscopic myotomy (POEM) might be a safe and ef
25 Emerging therapies, including gastric
peroral endoscopic myotomy and ghrelin agonists, show pr
26 Effect of
peroral endoscopic myotomy vs pneumatic dilation on symp
27 eroral endoscopic myotomy (POEM) and gastric
peroral endoscopic myotomy(G-POEM) procedures.
28 or ZD, while focusing specifically on Zenker
peroral endoscopic myotomy.
29 ne disease not amenable to surgical therapy,
peroral endoscopic removal, or simple percutaneous retri
30 After
peroral entry into mice, reovirus replicates within the
31 with vehicle or pazopanib (2.5 mg per mouse
peroral every other day) was initiated.
32 We hypothesized that
peroral FMTs create host-microbe mismatches that impact
33 almonella enterica serovar Typhimurium SR-11
peroral infection of BALB/c mice.
34 al sections taken from Peyer's patches after
peroral infection of mice showed that, unlike its wild-t
35 athogenesis of acute toxoplasmosis following
peroral infection was examined in both genetically susce
36 Following
peroral infection with 10 cysts of the ME49 strain, all
37 orter time than did wild-type controls after
peroral infection with ME49 cysts.
38 ies the genetic susceptibility of B6 mice to
peroral infection with T. gondii, whereas the same cytok
39 in Peyer's patches in C57BL/6 mice following
peroral infection with T. gondii.
40 After
peroral infection with the ME49 strain of T. gondii, C57
41 a remarkable difference in susceptibility to
peroral infection with Toxoplasma gondii among inbred st
42 n in the small intestine following sublethal
peroral infection with Toxoplasma gondii and that this d
43 e small intestines in C57BL/6 mice following
peroral infection with Toxoplasma gondii, we performed s
44 ble of systemic spread in newborn mice after
peroral inoculation and produces lethal encephalitis.
45 K poliovirus was unstable in feces following
peroral inoculation of mice.
46 rus that infects Peyer's patches (PPs) after
peroral inoculation of mice.
47 Following
peroral inoculation of newborn mice, both viruses replic
48 After
peroral inoculation, reovirus strain type 1 Lang replica
49 drome virus and Vibrio infection compared to
peroral inoculation.
50 ne was equivalent for both strains following
peroral inoculation.
51 a chronic carrier state in BALB/c mice after
peroral inoculation.
52 stine or transmission to the brain following
peroral inoculation.
53 to confirm that non-endoscopic
peroral manometric placement of WC is as effective and b
54 ents were randomly assigned to either 7 d of
peroral metronidazole/amoxicillin AB treatment or no AB,
55 We developed the
Peroral Mucosal Epithelium Absorption Enhancer (PERMEATE
56 es that cause systemic disease in mice after
peroral (
p.o.) inoculation and primary replication in th
57 were randomly assigned to WC with unsedated
peroral placement or SC after esophageal manometry (ESM)
58 Eighteen (8%) of 219 groups performed
peroral pneumocolon examinations and 80 (37%) performed
59 The authors conclude that noninvasive
peroral portal venous phase CT enterography with use of
60 r Typhimurium SR-11 wild-type strain via the
peroral route and is highly attenuated via the intraperi
61 treated BALB/c mice infected via the natural
peroral route died within 8 days of infection.
62 nity following infection through the natural
peroral route.
63 This study investigates the effect of
peroral Salmonella enterica serovar Typhimurium infectio
64 o be superior to other imaging tests such as
peroral small-bowel examinations, conventional CT, and b
65 Monotherapy with
peroral stavudine capsules or peroral zidovudine capsule
66 ases the susceptibility of mice to a primary
peroral T. gondii infection with cysts and impairs their
67 f 490 mg/dl and consumed equivalent doses of
peroral Te.
68 A murine model of
peroral Toxoplasma gondii infection was used to determin
69 Cx. pipiens had poor
peroral vector competence and a higher VT rate as compar
70 ced and supports previous data demonstrating
peroral virulence attenuation of pmrH mutants.
71 The noninvasive
peroral water CT enterography protocol had similar accur
72 Unsedated
peroral WC insertion is better tolerated than SC pH-metr
73 notherapy with peroral stavudine capsules or
peroral zidovudine capsules.